A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Denmark's economic growth, which was driven by what economists described as an "exceptional surge" in pharmaceutical exports, ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Todays focus will be on GSK Pharma shares in light of the companys announced topline growth and profitability for the full ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

The company registered standalone net profits after tax of EGP 43.559 million in Q1 2025, compared to EGP 2.046 million in net losses during Q1 2024 ...

Charlie Carman consults the world's leading artificial intelligence chatbot to find out which UK income stocks it would buy ...